Begin main content

News and Events

Latest News

Drug Reimbursement Recommendation

August 29, 2019
Today, CADTH has issued final recommendations for: Daratumumab (Darzalex) in combination with bortezomib, melphalan and prednisone for newly diagnosed multiple myeloma Funding Request: In combination with bortezomib, melphalan and prednisone, for the treatment of patients with newly diagnosed multiple myeloma who are not suitable for autologou...

Call for Patient Input and Clinical Experts: Mayzent and brolucizumab

August 28, 2019
CADTH has received the following notice(s) of pending drug submission(s). Brand name Mayzent TBC Generic name siponimod brolucizumab Manufacturer Novartis Pharmaceuticals Canada Inc. Novartis Pharmaceuticals Canada Inc. Indication(s) For the treatment of patient with secondary progressive...

Upcoming Events

Why Organizations, Researchers, and Patients Are Falling Prey to Predatory Journals

October 10, 2019

This interactive talk will provide an overview of what predatory journals are and describe how they are having an impact on organizations, researchers, and patients. In doing so, the talk will touch on related topics including academic incentives, research funding, and science policy. It will discuss the impact of predatory journals on knowle...